Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Top Cited Papers
Open Access
- 21 August 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6506), 956-963
- https://doi.org/10.1126/science.abc7520
Abstract
Countermeasures to prevent and treat COVID-19 are a global health priority. We enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate antibody responses, adapted our high-throughput antibody generation pipeline to rapidly screen over 1800 antibodies, and established an animal model to test protection. We isolated potent neutralizing antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. We showed that passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters, as revealed by maintained weight and low lung viral titers in treated animals. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (UM1 AI144462)
- Bill and Melinda Gates Foundation (OPP 1170236)
- Bill and Melinda Gates Foundation (OPP 1206647)
- Bill and Melinda Gates Foundation (OPP1196345)
This publication has 26 references indexed in Scilit:
- Passive immunotherapy of viral infections: 'super-antibodies' enter the frayNature Reviews Immunology, 2018
- Biophysical properties of the clinical-stage antibody landscapeProceedings of the National Academy of Sciences of the United States of America, 2017
- Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine DesignPLoS Pathogens, 2016
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyScience, 2016
- Structural and molecular basis for Ebola virus neutralization by protective human antibodiesScience, 2016
- The Cytoplasmic Tail of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains a Novel Endoplasmic Reticulum Retrieval Signal That Binds COPI and Promotes Interaction with Membrane ProteinJournal of Virology, 2007
- Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian HamstersJournal of Virology, 2005
- Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S ProteinJournal of Virology, 2004
- The antiviral activity of antibodies in vitro and in vivoAdvances in Immunology, 2001
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPEDIATRICS, 1998